\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ patient\\ is\\ tender\\ to\\ palpation\\ over\\ the\\ dip\\ and\\ pip\\ joints\\ in\\ both\\ hands\\.\\ \\ no\\ significant\\ effusions\\ noted\\ over\\ the\\ joint\\ spaces\\.\\ \\ laboratory\\ results\\ reported\\ normal\\ esr\\ levels\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ \ \(0\)\
\-\ treatment\\ usually\\ begins\\ with\\ nsaids\\.\\ \\ for\\ more\\ advanced\\ cases\\,\\ or\\ for\\ those\\ not\\ responding\\ to\\ a\\ trial\\ of\\ nsaids\\,\\ dmards\\ such\\ as\\ methotrexate\\ are\\ used\\.\\ \\ anti\\ tnf\\ drugs\\ can\\ also\\ be\\ used\\,\\ as\\ is\\ the\\ case\\ with\\ this\\ patient\\.\\ \\ follow\\-up\\ should\\ include\\ periodic\\ radiographs\\ to\\ assess\\ the\\ progression\\ of\\ the\\ disease\\ and\\ response\\ to\\ therapy\\.\ \(0\)\
\-\ radiographic\\ findings\\:\\ \ \(0\)\
\-\ symmetric\\ joint\\ space\\ loss\\ in\\ the\\ distal\\ interphalangeal\\ joints\\ and\\ proximal\\ interphalangealjoints\\ bilaterally\\.\\ \\ erosions\\ involving\\ the\\ metacarpal\\ heads\\ and\\ fluffy\\ erosions\\ involving\\ the\\ ulnar\\ styloid\\.\\ \\ erosion\\ of\\ the\\ pisiforms\\ bilaterally\\.\\ \\ normal\\ bone\\ mineralization\\ and\\ no\\ remarkable\\ soft\\ tissue\\ changes\ \(0\)\
\-\ diagnosis\\:\ \(12\)\
\-\ psoriatic\\ arthritis\ \(11\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ psoriatic\\ arthritis\\,\\ \\ erosive\\ osteoarthritis\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ patient\\ with\\ known\\ psoriasis\\,\\ now\\ taking\\ enbrel\\.\\ \\ patient\\ presents\\ with\\ pain\\ and\\ stiffness\\ in\\ both\\ hands\\,\\ made\\ worse\\ by\\ inactivity\\ and\\ relieved\\ somewhat\\ by\\ movement\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ psoriatic\\ arthritis\\ is\\ an\\ inflammatory\\ arthritis\\ that\\ accompanies\\ psoriasis\\ in\\ up\\ to\\ 30\\%\\ of\\ patients\\ with\\ the\\ disease\\.\\ \\ most\\ patients\\ with\\ psoriatic\\ arthritis\\ are\\ negative\\ for\\ rheumatoid\\ factor\\,\\ but\\ up\\ to\\ 10\\%\\ can\\ be\\ positive\\ for\\ rf\\.\\ \\ psoriatic\\ arthritis\\ affects\\ both\\ sexes\\ equally\\.\\ \\ the\\ clinical\\ presentation\\ is\\ usually\\ of\\ joint\\ pain\\ and\\ stiffness\\ upon\\ awakening\\ and\\ following\\ periods\\ of\\ inactivity\\,\\ alleviated\\ by\\ movement\\.\\ \\ the\\ distribution\\ is\\ often\\ asymmetric\\,\\ and\\ the\\ degree\\ of\\ pain\\ and\\ tenderness\\ is\\ usually\\ less\\ than\\ ra\\.\\ \\ the\\ typical\\ patterns\\ of\\ presentation\\ are\\ polyarthritis\\,\\ similar\\ to\\ ra\\,\\ and\\ oligoarthritis\\,\\ in\\ which\\ less\\ than\\ five\\ joints\\ are\\ affected\\ in\\ an\\ asymmetric\\ fashion\\.\\ \\ mutilating\\ arthritis\\ is\\ not\\ as\\ common\\ as\\ in\\ ra\\.\\ \\ involvement\\ of\\ the\\ dip\\ joints\\ also\\ differentiates\\ pa\\ from\\ ra\\.\ \(0\)\
\-\ gladman\\,\\ dd\\,\\ farewell\\,\\ v\\,\\ buskila\\,\\ d\\,\\ et\\ al\\.\\ reliability\\ of\\ measurements\\ of\\ active\\ and\\ damaged\\ joints\\ in\\ psoriatic\\ arthritis\\.\\ j\\ rheumatol\\ 1990\\;\\ 17\\:62\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ arthritis\\:\\ 0\\.3343709493373462\ \(0\)\
\-\ psoriatic\\:\\ 0\\.3311691177312331\ \(0\)\
\-\ joints\\:\\ 0\\.22085067315267398\ \(0\)\
\-\ ra\\:\\ 0\\.20328408784189722\ \(0\)\
\-\ and\\:\\ 0\\.15928465147389864\ \(0\)\
\-\ inactivity\\:\\ 0\\.15705997750890394\ \(0\)\
\-\ the\\:\\ 0\\.15381051386852157\ \(0\)\
\-\ in\\:\\ 0\\.1278399856542727\ \(0\)\
\-\ psoriasis\\:\\ 0\\.12689902120043764\ \(0\)\
\-\ dip\\:\\ 0\\.11959353280466309\ \(0\)\
\-\ stiffness\\:\\ 0\\.11084587081520067\ \(0\)\
\-\ of\\:\\ 0\\.1106233177743166\ \(0\)\
\-\ erosions\\:\\ 0\\.10308421751463649\ \(0\)\
\-\ up\\:\\ 0\\.10168146892490028\ \(0\)\
\-\ joint\\:\\ 0\\.10158879597632513\ \(0\)\
\-\ nsaids\\:\\ 0\\.1005660495446314\ \(0\)\
\-\ is\\:\\ 0\\.09851322826218276\ \(0\)\
\-\ hands\\:\\ 0\\.09745599059430578\ \(0\)\
\-\ usually\\:\\ 0\\.09705446974814702\ \(0\)\
\-\ movement\\:\\ 0\\.09461590300183587\ \(0\)\
\-\ asymmetric\\:\\ 0\\.09249374111170039\ \(0\)\
\-\ include\\:\\ 0\\.09172855801063651\ \(0\)\
\-\ to\\:\\ 0\\.08993062832435063\ \(0\)\
\-\ both\\:\\ 0\\.08597165063888977\ \(0\)\
\-\ as\\:\\ 0\\.08257967757669628\ \(0\)\
\-\ interphalangealjoints\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ pisiforms\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ oligoarthritis\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ mutilating\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ gladman\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ farewell\\:\\ 0\\.08218273295233924\ \(0\)\
\-\ can\\:\\ 0\\.08090248375849848\ \(0\)\
\-\ dmards\\:\\ 0\\.07852998875445197\ \(0\)\
\-\ enbrel\\:\\ 0\\.07852998875445197\ \(0\)\
\-\ accompanies\\:\\ 0\\.07852998875445197\ \(0\)\
\-\ awakening\\:\\ 0\\.07852998875445197\ \(0\)\
\-\ buskila\\:\\ 0\\.07852998875445197\ \(0\)\
\-\ are\\:\\ 0\\.07799966069555266\ \(0\)\
\-\ for\\:\\ 0\\.07787856406858844\ \(0\)\
\-\ used\\:\\ 0\\.07694376159478318\ \(0\)\
\-\ polyarthritis\\:\\ 0\\.07593832550163243\ \(0\)\
\-\ laboratory\\:\\ 0\\.07463488765736626\ \(0\)\
\-\ sexes\\:\\ 0\\.07392807530732595\ \(0\)\
\-\ rheumatol\\:\\ 0\\.07392807530732595\ \(0\)\
\-\ tnf\\:\\ 0\\.07228558130374517\ \(0\)\
\-\ fluffy\\:\\ 0\\.07228558130374517\ \(0\)\
\-\ dd\\:\\ 0\\.07228558130374517\ \(0\)\
\-\ involving\\:\\ 0\\.0719906378935873\ \(0\)\
\-\ presentation\\:\\ 0\\.07075111994605383\ \(0\)\
\-\ less\\:\\ 0\\.06992202002896412\ \(0\)\
\-\ alleviated\\:\\ 0\\.0686328371058579\ \(0\)\
\-\ differentiates\\:\\ 0\\.0686328371058579\ \(0\)\
\-\ bilaterally\\:\\ 0\\.06854596596388142\ \(0\)\
\-\ patient\\:\\ 0\\.06685748251097949\ \(0\)\
\-\ reliability\\:\\ 0\\.0668250398284166\ \(0\)\
\-\ by\\:\\ 0\\.06546867530710225\ \(0\)\
\-\ responding\\:\\ 0\\.06532008705619442\ \(0\)\
\-\ age\\:\\ 0\\.06452546557526842\ \(0\)\
\-\ damaged\\:\\ 0\\.06403092365873186\ \(0\)\
\-\ periods\\:\\ 0\\.06290335698265521\ \(0\)\
\-\ styloid\\:\\ 0\\.06190135018803648\ \(0\)\
\-\ interphalangeal\\:\\ 0\\.06143926040591233\ \(0\)\
\-\ rf\\:\\ 0\\.06143926040591233\ \(0\)\
\-\ with\\:\\ 0\\.06037604464381454\ \(0\)\
\-\ pip\\:\\ 0\\.06018017642090978\ \(0\)\
\-\ equally\\:\\ 0\\.059796766402331544\ \(0\)\
\-\ measurements\\:\\ 0\\.059796766402331544\ \(0\)\
\-\ fashion\\:\\ 0\\.059429010211605834\ \(0\)\
\-\ 1990\\:\\ 0\\.05907567960548761\ \(0\)\
\-\ than\\:\\ 0\\.058262305044640215\ \(0\)\
\-\ patients\\:\\ 0\\.05781862199093851\ \(0\)\
\-\ methotrexate\\:\\ 0\\.05778651620802505\ \(0\)\
\-\ periodic\\:\\ 0\\.05778651620802505\ \(0\)\
\-\ patterns\\:\\ 0\\.05778651620802505\ \(0\)\
\-\ metacarpal\\:\\ 0\\.05749112005020208\ \(0\)\
\-\ trial\\:\\ 0\\.057205103149512014\ \(0\)\
\-\ over\\:\\ 0\\.05714945829759502\ \(0\)\
\-\ begins\\:\\ 0\\.056397807315251014\ \(0\)\
\-\ heads\\:\\ 0\\.055422935407600335\ \(0\)\
\-\ mineralization\\:\\ 0\\.055422935407600335\ \(0\)\
\-\ pain\\:\\ 0\\.055166984966212765\ \(0\)\
\-\ erosive\\:\\ 0\\.05454333233927652\ \(0\)\
\-\ relieved\\:\\ 0\\.053935768970202976\ \(0\)\
\-\ diagnosis\\:\\ 0\\.05327973327691971\ \(0\)\
\-\ affects\\:\\ 0\\.05265967123951568\ \(0\)\
\-\ case\\:\\ 0\\.05163488542777831\ \(0\)\
\-\ drugs\\:\\ 0\\.05139319998418331\ \(0\)\
\-\ findings\\:\\ 0\\.05072539537696974\ \(0\)\
\-\ remarkable\\:\\ 0\\.05068348072911571\ \(0\)\
\-\ gestational\\:\\ 0\\.04989961475373747\ \(0\)\
\-\ taking\\:\\ 0\\.04977535380900769\ \(0\)\
\-\ treatment\\:\\ 0\\.048958933414720456\ \(0\)\
\-\ ulnar\\:\\ 0\\.048838533808669725\ \(0\)\
\-\ also\\:\\ 0\\.04834414009469307\ \(0\)\
\-\ advanced\\:\\ 0\\.04829892488856971\ \(0\)\
\-\ factor\\:\\ 0\\.04819477603308529\ \(0\)\
\-\ effusions\\:\\ 0\\.04809181747629618\ \(0\)\
\-\ erosion\\:\\ 0\\.04769136151949616\ \(0\)\
\-\ assess\\:\\ 0\\.04749761694131043\ \(0\)\
\-\ anti\\:\\ 0\\.04740228509231637\ \(0\)\
\-\ response\\:\\ 0\\.04740228509231637\ \(0\)\
\-\ progression\\:\\ 0\\.04712219696818938\ \(0\)\
\-\ esr\\:\\ 0\\.04703073653122843\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.046940195310192216\ \(0\)\
\-\ spaces\\:\\ 0\\.04676179788335432\ \(0\)\
\-\ somewhat\\:\\ 0\\.04676179788335432\ \(0\)\
\-\ five\\:\\ 0\\.04641526378880888\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.04529770130661143\ \(0\)\
\-\ discussion\\:\\ 0\\.04500230514878846\ \(0\)\
\-\ degree\\:\\ 0\\.044929945115885724\ \(0\)\
\-\ symmetric\\:\\ 0\\.04403861732160889\ \(0\)\
\-\ those\\:\\ 0\\.043973571727388666\ \(0\)\
\-\ distribution\\:\\ 0\\.043592862585959256\ \(0\)\
\-\ disease\\:\\ 0\\.04314283379380399\ \(0\)\
\-\ worse\\:\\ 0\\.04305036438563486\ \(0\)\
\-\ affected\\:\\ 0\\.04226649841025661\ \(0\)\
\-\ normal\\:\\ 0\\.04196384118729057\ \(0\)\
\-\ be\\:\\ 0\\.0416931969409173\ \(0\)\
\-\ references\\:\\ 0\\.0409701880265704\ \(0\)\
\-\ al\\:\\ 0\\.04083194323195928\ \(0\)\
\-\ levels\\:\\ 0\\.04074094472427224\ \(0\)\
\-\ not\\:\\ 0\\.04057457347366177\ \(0\)\
\-\ upon\\:\\ 0\\.04042949924124135\ \(0\)\
\-\ et\\:\\ 0\\.04025624821595013\ \(0\)\
\-\ results\\:\\ 0\\.04004426724355641\ \(0\)\
\-\ typical\\:\\ 0\\.039715142945765704\ \(0\)\
\-\ made\\:\\ 0\\.03963470691441767\ \(0\)\
\-\ pa\\:\\ 0\\.039436703874482865\ \(0\)\
\-\ an\\:\\ 0\\.039302217831948344\ \(0\)\
\-\ similar\\:\\ 0\\.03916661328291273\ \(0\)\
\-\ active\\:\\ 0\\.03816060614379557\ \(0\)\
\-\ radiographic\\:\\ 0\\.03812667474525474\ \(0\)\
\-\ tender\\:\\ 0\\.037568575788046024\ \(0\)\
\-\ involvement\\:\\ 0\\.03719445522004224\ \(0\)\
\-\ reported\\:\\ 0\\.037013064347201585\ \(0\)\
\-\ or\\:\\ 0\\.03575486865325947\ \(0\)\
\-\ this\\:\\ 0\\.03531660138709743\ \(0\)\
\-\ now\\:\\ 0\\.035276288713287585\ \(0\)\
\-\ 30\\:\\ 0\\.035056848957318955\ \(0\)\
\-\ inflammatory\\:\\ 0\\.034749029042088354\ \(0\)\
\-\ palpation\\:\\ 0\\.03465639300051894\ \(0\)\
\-\ cases\\:\\ 0\\.03456469983578671\ \(0\)\
\-\ space\\:\\ 0\\.034206984330257297\ \(0\)\
\-\ positive\\:\\ 0\\.033862931992108374\ \(0\)\
\-\ should\\:\\ 0\\.03353153736137591\ \(0\)\
\-\ often\\:\\ 0\\.03353153736137591\ \(0\)\
\-\ no\\:\\ 0\\.033422453504134766\ \(0\)\
\-\ differential\\:\\ 0\\.03339029946371086\ \(0\)\
\-\ radiographs\\:\\ 0\\.03333044026897898\ \(0\)\
\-\ known\\:\\ 0\\.03327097618732198\ \(0\)\
\-\ such\\:\\ 0\\.03305623897330897\ \(0\)\
\-\ clinical\\:\\ 0\\.03256814426128853\ \(0\)\
\-\ days\\:\\ 0\\.03253167143550833\ \(0\)\
\-\ tenderness\\:\\ 0\\.03222747334668478\ \(0\)\
\-\ proximal\\:\\ 0\\.032105140856562055\ \(0\)\
\-\ negative\\:\\ 0\\.03181478551337909\ \(0\)\
\-\ loss\\:\\ 0\\.03130826581659479\ \(0\)\
\-\ changes\\:\\ 0\\.031057570664886232\ \(0\)\
\-\ following\\:\\ 0\\.030828715623351335\ \(0\)\
\-\ weeks\\:\\ 0\\.030798636210891326\ \(0\)\
\-\ 10\\:\\ 0\\.030049872662133006\ \(0\)\
\-\ months\\:\\ 0\\.0299127501417346\ \(0\)\
\-\ distal\\:\\ 0\\.02985848024470801\ \(0\)\
\-\ significant\\:\\ 0\\.02967106953481468\ \(0\)\
\-\ therapy\\:\\ 0\\.029526505481157456\ \(0\)\
\-\ common\\:\\ 0\\.029143638699873232\ \(0\)\
\-\ these\\:\\ 0\\.029019548918885682\ \(0\)\
\-\ more\\:\\ 0\\.028218240971626403\ \(0\)\
\-\ bone\\:\\ 0\\.028039622467826514\ \(0\)\
\-\ physical\\:\\ 0\\.027864476719660424\ \(0\)\
\-\ soft\\:\\ 0\\.027358587995967\ \(0\)\
\-\ noted\\:\\ 0\\.0272465497715014\ \(0\)\
\-\ tissue\\:\\ 0\\.02695768644620721\ \(0\)\
\-\ most\\:\\ 0\\.02674456568514279\ \(0\)\
\-\ exam\\:\\ 0\\.02586941656379247\ \(0\)\
\-\ but\\:\\ 0\\.025412106088360583\ \(0\)\
\-\ presents\\:\\ 0\\.024720922384485693\ \(0\)\
\-\ which\\:\\ 0\\.023367241582159907\ \(0\)\
\-\ that\\:\\ 0\\.022301043883363233\ \(0\)\
\-\ from\\:\\ 0\\.02040966488162291\ \(0\)\
\-\ history\\:\\ 0\\.019633700648407623\ \(0\)\
